BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34256813)

  • 1. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    Ding T; Tang D; Xi M
    J Ovarian Res; 2021 Jul; 14(1):93. PubMed ID: 34256813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
    Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
    So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
    J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients.
    Takahashi A; Kato K; Matsuura M; Katsuda T; Matoda M; Nomura H; Okamoto S; Kanao H; Kondo E; Omatsu K; Utsugi K; Takeshima N
    Medicine (Baltimore); 2017 Sep; 96(37):e8006. PubMed ID: 28906381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    Int J Gynecol Cancer; 2023 Sep; 33(9):1440-1447. PubMed ID: 37567595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Marchetti C; Fagotti A; Tombolini V; Scambia G; De Felice F
    Ann Surg Oncol; 2021 Jun; 28(6):3258-3263. PubMed ID: 33067742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.
    Zhang G; Zhu Y; Liu C; Chao G; Cui R; Zhang Z
    J Ovarian Res; 2019 Apr; 12(1):33. PubMed ID: 30995948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
    Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
    N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
    da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
    Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Mar; 3(3):CD004706. PubMed ID: 22419298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.
    Galaal K; Naik R; Bristow RE; Patel A; Bryant A; Dickinson HO
    Cochrane Database Syst Rev; 2010 Jun; 2010(6):CD007822. PubMed ID: 20556785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.